Onconetix (ONCO) Common Equity (2021 - 2026)
Onconetix (ONCO) posted quarterly Common Equity of $11.7 million for Q1 2026, up 194.19% year-over-year from $4.0 million in Q1 2025, and down 25.49% quarter-over-quarter from $15.8 million in Q4 2025.
Onconetix (ONCO) Common Equity (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Common Equity for 6 consecutive years, with $11.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 194.19% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.7 million (up 194.19% YoY), while the FY2025 annual figure was $15.8 million, up 84.54% from the prior year.
- Common Equity slipped to $11.7 million in Q1 2026 per ONCO's latest filing, from $15.8 million in the prior quarter.
- Across five years, Common Equity topped out at $41.0 million in Q3 2024 and bottomed at -$28.7 million in Q2 2024.
- Historically, Common Equity has averaged $10.4 million across 5 years, with a median of $11.7 million in 2026.
- Annual changes were most pronounced in 2022 — Common Equity soared 1447.65% — and 2024, when it sank 319.71%.
- Onconetix's Common Equity stood at $22.4 million in 2022, then tumbled by 93.73% to $1.4 million in 2023, then soared by 508.24% to $8.5 million in 2024, then jumped by 84.54% to $15.8 million in 2025, then slipped by 25.49% to $11.7 million in 2026.
- Business Quant data shows ONCO's Common Equity at $11.7 million in Q1 2026, $15.8 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 13.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.47 Mn |
| Mar 31, 2026 | 11.75 Mn |
| Dec 31, 2025 | 15.76 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 5.91 Mn |
| Mar 31, 2025 | 3.99 Mn |
| Dec 31, 2024 | 8.54 Mn |
| Sep 30, 2024 | 41.02 Mn |
| Jun 30, 2024 | -28.73 Mn |
| Mar 31, 2024 | -14.50 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 10.24 Mn |
| Jun 30, 2023 | 13.08 Mn |
| Mar 31, 2023 | 19.69 Mn |
| Dec 31, 2022 | 22.39 Mn |
| Sep 30, 2022 | 25.73 Mn |
| Jun 30, 2022 | 20.57 Mn |
| Mar 31, 2022 | 16.53 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 2.63 Mn |